EX-23.1 2 brhc10039222_ex23-1.htm EXHIBIT 23.1

EXHIBIT 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in the Registration Statement of Brooklyn ImmunoTherapeutics, Inc. on Form S-8 (File No. 333-260200; File No. 333-256760; and File No. 333-232141) and Form S-3 (File No. 333-264585) of our report dated April 15, 2022, except for Note 3, Restatement of Previously Reported Information and Note 15, Income Taxes, as to which the date is June 30, 2022, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Brooklyn ImmunoTherapeutics, Inc. as of December 31, 2021 and 2020 and for each of the two years in the period ended December 31, 2021, which report is included in this Annual Report on Form 10-K/A of Brooklyn ImmunoTherapeutics, Inc. for the year ended December 31, 2021. We were dismissed as auditors on April 15, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements appearing in such Prospectus for the periods after the date of our dismissal.
Our report on the consolidated financial statements refers to a change in the method of accounting for leases in 2020 due to the adoption of the guidance in ASC Topic 842, Leases (“Topic 842”).
/s/ Marcum llp
Marcum llp
New York, NY
June 30, 2022